Immunicum AB (publ) said the U.S. FDA cleared the company's investigational new drug application for INTUVAX for the treatment of metastatic renal cell cancer.
The clearance enables the company to expand its ongoing phase 2 study in the U.S.
Discover more about S&P Global’s offerings